湖南银泽华浩生物科技

Hunan Yinze Huahao Biotechnology is a Chinese biopharmaceutical company specializing in the development of next-generation cell therapies, particularly "off-the-shelf" universal CAR-T (UCAR-T) and CAR-NK products. Based in Changsha, the company leverages its proprietary YZ-CAR platform to address limitations of traditional autologous cell therapies, such as high costs and long manufacturing times. Their pipeline targets a range of hematological malignancies and solid tumors, including B-cell lymphoma, multiple myeloma, and gastric cancer. The company is actively advancing several candidates through pre-clinical development and investigator-initiated trials. They are a key participant in the growing biotech ecosystem within the Hunan High-tech Development Zone.